Interval debulking surgery: An alternative for primary surgical debulking?

Seminars in Surgical Oncology

Volumn 19, Issue 1, 2000, Pages 49-53

  Vergote, Ignace ^a   De Wever, Ivo ^a   Tjalma, Wiebren ^b   Van Gramberen, Marleen ^a   DeCloedt, Jan ^a,c   Van Dam, Peter ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c St Blasius Hospital   (Belgium)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

Author keywords

Adjuvant chemotherapy; Age; Ascites; Carcinoma pathology surgery; Combined modality therapy; Laparoscopy; Neoplasm metastasis; Neoplasm staging; Ovarian neoplasms surgery; Peritoneal metastasis; Prognosis; Reoperation; Surgical instruments; Survival analysis

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL;

AGE; ASCITES; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; HUMAN; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; PERITONEUM METASTASIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LAPAROTOMY; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0033949465     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2388(200007/08)19:1<49::AID-SSU8>3.0.CO;2-Z     Document Type: Review

References (35)

1. Aure JC, Hoeg K, Kolstad P: Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:1-9.
2. Griffiths CT, Fuller AF: Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 1978;58:131-142.
3. van der Burg ME, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-634.
4. Smith JP, Day TG Jr: Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 1979;135:984-993.
5. Bertelsen K, Jacobsen A, Andersen JE, et al: A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987;28:161-9.
6. Randomised comparison of cisplatin with cyclophosphamide/ cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Lancet 1987;2(8555)353-359.
7. Voest EE, van Houwelingen JC, Neijt JP: A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log [relative risk]) as main objectives. Eur J Cancer Clin Oncol 1989;25:711-720.
8. Hunter RW, Alexander ND, Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-511.
9. Heintz AP, Hacker NF, Berek JS, et al: Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986;67:783-788.
10. Vergote I, De Wever I, Tjalma W, et al: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-436.
11. Piver MS, Lele SB, Marchetti DL, et al: The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988;6:983-989.
12. Potter ME, Patridge EE, Hatch KD, et al: Primary surgical therapy of ovarian cancer: how much and when? Gynecol Oncol 1991;40: 195-200.
13. Meerpohl HG, Sauerbrei W, Schumacher M, Pfleiderer A: Welche parameter beinflussen die Grosse des postoperativen Tumorrestes beim fortgeschrittenen Ovarialkarzinom. Arch Gynecol Obstet 1991;250:174-175. (Ger)
14. Tulusan AH, Neumann-Kleen, Adam R, et al: Morbidität der radikalen Krebschirurgie des Ovarial-Karzinoms. Arch Gynecol Obstet 1991;250:171-172. (Ger)
15. Rath W, Meden H, Brill A, Kuhn W: Ergebnisse bei der operativen Primaritherapie des Ovarialkarzinoms. Arch Gynecol Obstet 1991;250:175-176. (Ger)
16. Eisenkop SM, Spirtos NM, Montag TW, et al: The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-209.
17. Redman JR, Petroni GR, Saigo PE, et al: Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 1986;4:515-523.
18. Neijt JP, ten Bokkel Huinink WW, van der Burg ME: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5:1157-1168.
19. Hacker NF, Berek JS, Lagasse LD, et al: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-420.
20. Heintz AP, Van Oosterom AT, Trimbos JB, et al: The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol 1988;30:347-358.
21. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study, Gynecol Oncol 1992;47:159-166.
22. Burghardt E, Girardi F, Lahousen M, et al: Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991;40:103-106.
23. Friedlander ML, Hedley DW, Swanson C, Russell P: Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988;6:282-290.
24. Webb MJ: Cytoreduction in ovarian cancer: achievability and results [Review]. Ballieres Clin Obstet Gynecol 1989;3:83-94.
25. Farias-Eisner R, Teng F, Oliveira M, et al: The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994;55:108-110.
26. Eisenkop SM, Nalick RH, Wang H, Teng NN: Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993;51:224-229.
27. van Dam PA, Tjalma W, Weyler J, et al: Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized study. Am J Obstet Gynecol 1996;174:943-950.
28. Lawton FG, Redman CW, Luesley DM, et al: Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989;73:61-65.
29. Jacob JH, Gershenson DM, Morris M, et al: Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer. Gynecol Oncol 1991;42:146-150.
30. Lim JT, Green JA: Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (R Coll Radiol) 1993;5:198-202.
31. Shimizu Y, Hasumi K: [Treatment of stage III and IV ovarian cancer - is neoadjuvant chemotherapy effective?] Nippon Sanka Fujinka Gakkai Zasshi 1993; 45:1007-1014. (Jpn)
32. Onnis A, Marchetti M, Padovan P, Castellan L: Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynecol Oncol 1996;17:393-396.
33. Surwit E, Childers J, Atlas I, et al: Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynaecol Cancer 1996;6:356-361.
34. Schwanz PE, Rutherford TJ, Chambers JT, et al: Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72:93-99.
35. van Dam PA, DeCloedt J, Tjalma WA, et al: Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced? Am J Obstet Gynecol 1999;181: 536-541.